triamcinolone acetonide + anti-VEGF agent

Triamcinolone acetonide + anti-VEGF agent is a combination therapy, typically administered intravitreally, for retinal diseases characterized by macular edema, neovascularization, or inflammation (such as diabetic macular edema, radiation maculopathy, and branch retinal vein occlusion). Triamcinolone acetonide is a synthetic corticosteroid with potent anti-inflammatory and angiostatic activity, working by upregulating extracellular matrix proteins (like plasminogen activator inhibitor) and suppressing inflammatory cytokines and VEGF synthesis. Anti-VEGF agents (such as bevacizumab, ranibizumab, aflibercept, conbercept) inhibit vascular endothelial growth factor (VEGF), reducing abnormal blood vessel growth and vascular permeability. Together, these drugs act synergistically to lower inflammation, stabilize macular edema, and suppress angiogenesis, often reducing the need for repeated anti-VEGF injections, while preserving or improving visual acuity in some patient populations[1][3][4].

Other names

Anti-VEGF/Triamcinolone combination therapy